Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mabpharm Limited ( (HK:2181) ) has provided an announcement.
Mabpharm Limited has announced that its board of directors will convene on March 26, 2025, to review and approve the company’s annual financial results for the year ending December 31, 2024. This meeting is significant as it will address the company’s financial performance and any other business matters, potentially impacting its market positioning and stakeholder interests.
More about Mabpharm Limited
Mabpharm Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development and commercialization of innovative drugs, primarily targeting the healthcare market.
YTD Price Performance: 96.43%
Average Trading Volume: 109,375
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$2.02B
For a thorough assessment of 2181 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue